Xu, JiangshengLiu, YunhuaLi, YujingWang, HaiStewart, SamanthaVan der Jeught, KevinAgarwal, PranayZhang, YuntianLiu, ShengZhao, GangWan, JunLu, XiongbinHe, Xiaoming2019-10-102019-10-102019-04Xu, J., Liu, Y., Li, Y., Wang, H., Stewart, S., Van der Jeught, K., … He, X. (2019). Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nature nanotechnology, 14(4), 388–397. doi:10.1038/s41565-019-0381-6https://hdl.handle.net/1805/21103TP53 is the most frequently mutated or deleted gene in triple negative breast cancer (TNBC). Both the loss of TP53 and the lack of targeted therapy are significantly correlated with poor clinical outcomes, making TNBC the only type of breast cancer that has no approved targeted therapies. Through in silico analysis, we identified POLR2A in the TP53-neighbouring region as a collateral vulnerability target in TNBC tumours, suggesting that its inhibition via small interfering RNA (siRNA) may be an amenable approach for TNBC targeted treatment. To enhance bioavailability and improve endo/lysosomal escape of siRNA, we designed pH-activated nanoparticles for augmented cytosolic delivery of POLR2A siRNA (siPol2). Suppression of POLR2A expression with the siPol2-laden nanoparticles leads to enhanced growth reduction of tumours characterized by hemizygous POLR2A loss. These results demonstrate the potential of the pH-responsive nanoparticle and the precise POLR2A targeted therapy in TNBC harbouring the common TP53 genomic alteration.en-USPublisher PolicyCell Line -- TumorCell ProliferationDNA-Directed RNA PolymerasesEndosomesHydrogen-Ion ConcentrationLysosomesNanoparticlesTriple Negative Breast NeoplasmsTumor Suppressor Protein p53Article